BBC News

GPs get 3,000 bonus to maximise weight loss drug prescriptions

Sky News

GP practices to be offered 3,000 bonus for prescribing weight loss jabs

Independent

GPs to be offered bonuses to speed up weight-loss drug roll-out

The Times

Bonuses for GPs who speed up prescription of weight-loss jabs

The Telegraph

GPs to be paid to prescribe weight-loss jabs

Daily Mail

GPs will receive bonuses worth millions of pounds if they prescribe fat jabs to their most obese patients

NHS England

Interim commissioning guidance

Pulse

Weight Loss Drug Prescribing To Be Added To Qof As Part Of 2026 27 Gp Contract

Weight management injections

Nhs.Uk

Mounjaro (Tirzepatide)

National Pharmacy Association

Weight Loss Pharmacies Respond To Government Gp Funding Package

BBCBreakfast

UnityNewsNet

committees.parliament.uk

Metaculus

What Will Be The Reported Q1 2026 Global Revenue For Mounjaro

The British government announced on Tuesday that GP surgeries will receive financial incentives of up to £3,000 ($4,050.81) for prescribing weight-loss medications, namely Mounjaro, to eligible patients as part of a new NHS contract.

The British government announced on Tuesday that GP surgeries will receive financial incentives of up to £3,000 ($4,050.81) for prescribing weight-loss medications, namely Mounjaro, to eligible patients as part of a new NHS contract.

The scheme is backed by £25 million in government funding, with GPs also set to receive an additional £1,000 per year in reward payments for referring their patients to weight-loss programs.

The scheme is backed by £25 million in government funding, with GPs also set to receive an additional £1,000 per year in reward payments for referring their patients to weight-loss programs.

In a statement issued to multiple media outlets, Health Secretary Wes Streeting clarified that the incentives aim to bring fairness to obesity treatment in the U.K. — based on need rather than ability to pay — to "ease the £11 billion burden obesity places on the health service and economy."

In a statement issued to multiple media outlets, Health Secretary Wes Streeting clarified that the incentives aim to bring fairness to obesity treatment in the U.K. — based on need rather than ability to pay — to "ease the £11 billion burden obesity places on the health service and economy."

The NHS first began rolling out Mounjaro in June 2025, with a phased implementation planned over 12 years, focusing on specialist NHS weight management services and primary care services, such as GPs.

The NHS first began rolling out Mounjaro in June 2025, with a phased implementation planned over 12 years, focusing on specialist NHS weight management services and primary care services, such as GPs.

Despite this, the implementation process only allows 220,000 people to receive Mounjaro treatment on the NHS in its first three years, with the majority of the nearly 2.4 million people estimated to be using weight-loss drugs in the U.K. accessing treatment privately.

Despite this, the implementation process only allows 220,000 people to receive Mounjaro treatment on the NHS in its first three years, with the majority of the nearly 2.4 million people estimated to be using weight-loss drugs in the U.K. accessing treatment privately.

To be eligible for Mounjaro on the NHS, patients must be diagnosed with a BMI of at least 40, or 37.5 for those from a minority ethnic background, and at least four weight-related health conditions, including type 2 diabetes, hypertension, dyslipidaemia, established cardiovascular disease or obstructive sleep apnoea.

To be eligible for Mounjaro on the NHS, patients must be diagnosed with a BMI of at least 40, or 37.5 for those from a minority ethnic background, and at least four weight-related health conditions, including type 2 diabetes, hypertension, dyslipidaemia, established cardiovascular disease or obstructive sleep apnoea.

BBC News #

Sky News #

Independent #

The Times #

The Telegraph #

Daily Mail #

NHS England #

Pulse #

Nhs.Uk #

National Pharmacy Association #

committees.parliament.uk #

Metaculus #

GP practices in England will receive financial incentives of up to 3,000 annually for prescribing weight loss medications like Mounjaro to eligible patients and referring them to weight management services. The scheme is backed by 25 million in ring-fenced funding.

GP practices in England will receive financial incentives of up to 3,000 annually for prescribing weight loss medications like Mounjaro to eligible patients and referring them to weight management services. The scheme is backed by 25 million in ring-fenced funding.

Health Secretary Wes Streeting stated that access to weight loss drugs should be based on need rather than ability to pay, noting concerns about rogue prescribers selling dangerous unlicensed drugs outside the NHS. The incentives aim to bring fairness to obesity treatment.

Health Secretary Wes Streeting stated that access to weight loss drugs should be based on need rather than ability to pay, noting concerns about rogue prescribers selling dangerous unlicensed drugs outside the NHS. The incentives aim to bring fairness to obesity treatment.

The NHS began rolling out Mounjaro in June with strict eligibility criteria requiring patients to have a BMI over 40 and at least four weight-related health conditions. An estimated 2.4 million people in the UK are taking weight loss drugs, with most accessing them privately.

The NHS began rolling out Mounjaro in June with strict eligibility criteria requiring patients to have a BMI over 40 and at least four weight-related health conditions. An estimated 2.4 million people in the UK are taking weight loss drugs, with most accessing them privately.

NHS England has implemented a phased 12-year rollout of Mounjaro, prioritizing 220,000 patients in the first three years. Current data suggests that even eligible patients cannot access the drug, and not all GP practices currently prescribe weight loss medications.

NHS England has implemented a phased 12-year rollout of Mounjaro, prioritizing 220,000 patients in the first three years. Current data suggests that even eligible patients cannot access the drug, and not all GP practices currently prescribe weight loss medications.

Professor Victoria Tzortziou Brown of the Royal College of GPs cautioned that widening the rollout could increase workload unsustainably and raise unrealistic patient expectations. She emphasized that GPs make prescribing decisions based on clinical judgment, not financial incentives.

Professor Victoria Tzortziou Brown of the Royal College of GPs cautioned that widening the rollout could increase workload unsustainably and raise unrealistic patient expectations. She emphasized that GPs make prescribing decisions based on clinical judgment, not financial incentives.

Two new Quality and Outcomes Framework indicators will track obesity care provision in the 2026/27 GP contract, including BMI recording and appropriate weight management support. The eligibility threshold will drop to BMI 35 with four comorbidities from 2026/27.

Two new Quality and Outcomes Framework indicators will track obesity care provision in the 2026/27 GP contract, including BMI recording and appropriate weight management support. The eligibility threshold will drop to BMI 35 with four comorbidities from 2026/27.

Weight loss jabs have proven hugely impactful with encouraging evidence for treating obesity and related health conditions. Expanding NHS access ensures healthcare remains based on need rather than ability to pay, preventing a two-tier system where only the wealthy benefit from these effective treatments.

Weight loss jabs have proven hugely impactful with encouraging evidence for treating obesity and related health conditions. Expanding NHS access ensures healthcare remains based on need rather than ability to pay, preventing a two-tier system where only the wealthy benefit from these effective treatments.

BBC Breakfast

Paying GPs £3,000 bonuses to prescribe weight loss drugs creates dangerous financial incentives to push medications lacking long-term safety data. With hundreds already dead and injured from these treatments, this scheme prioritizes profit over patient safety and represents medical quackery.

Paying GPs £3,000 bonuses to prescribe weight loss drugs creates dangerous financial incentives to push medications lacking long-term safety data. With hundreds already dead and injured from these treatments, this scheme prioritizes profit over patient safety and represents medical quackery.

Unity Net News

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

United Kingdom

Health

This initiative is part of the government's strategy to tackle the burden of obesity on the U.K.'s health services and economy. By encouraging GPs to offer these life-altering medications to the wider public, the government can ensure that those who need this form of treatment but cannot afford it privately will receive it with wraparound support.

This initiative is part of the government's strategy to tackle the burden of obesity on the U.K.'s health services and economy. By encouraging GPs to offer these life-altering medications to the wider public, the government can ensure that those who need this form of treatment but cannot afford it privately will receive it with wraparound support.

While the NHS's rollout of weight-loss drugs remains painfully slow, with only a handful of patients treated, placing the burden on overstretched GPs is not the answer. The government should instead consider commissioning pharmacies, which can provide the sustainable weight-loss treatment required more quickly than the sluggish NHS system.

While the NHS's rollout of weight-loss drugs remains painfully slow, with only a handful of patients treated, placing the burden on overstretched GPs is not the answer. The government should instead consider commissioning pharmacies, which can provide the sustainable weight-loss treatment required more quickly than the sluggish NHS system.

This scheme creates dangerous incentives by paying GPs thousands of pounds to prescribe medications without any long-term safety data. With hundreds already dead and injured as a result of these treatments, it is clear that the government is prioritizing corporate profit over patient safety by pushing this medical quackery.

This scheme creates dangerous incentives by paying GPs thousands of pounds to prescribe medications without any long-term safety data. With hundreds already dead and injured as a result of these treatments, it is clear that the government is prioritizing corporate profit over patient safety by pushing this medical quackery.

The reported Q1 2026 global revenue for Mounjaro will be $7.1 billion, according to the Metaculus prediction community.

The reported Q1 2026 global revenue for Mounjaro will be $7.1 billion, according to the Metaculus prediction community.

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

The Spin

Metaculus Prediction

Articles on this story

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

GPs to Get £3,000 Incentive for Weight Loss Drug Referrals

The Spin

Metaculus Prediction

Articles on this story

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters